<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002618</url>
  </required_header>
  <id_info>
    <org_study_id>9315</org_study_id>
    <secondary_id>POG-9315</secondary_id>
    <secondary_id>CDR0000063955</secondary_id>
    <nct_id>NCT00002618</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma</brief_title>
  <official_title>A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Giving the drugs in different doses may kill more cancer cells.

      PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with various
      combinations of drugs in treating pediatric patients with advanced-stage large cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the event free survival of children with advanced stage large cell
      lymphoma treated with modified APO (doxorubicin/prednisone/vincristine/mercaptopurine) with
      or without intermediate-dose methotrexate/high dose cytarabine as maintenance therapy
      following induction therapy with APO. II. Characterize further the immunophenotypic and
      morphologic correlates of pediatric large cell lymphoma.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two
      treatment arms, except for those with CNS disease. These patients are assigned to arm II and
      receive whole brain irradiation on Regimen B. Arm I: Induction (Modified APO): Patients
      receive vincristine IV on days 1, 8, 15, 22, and 29, doxorubicin IV over 15 minutes on days 1
      and 22, prednisone three times a day on days 1-28, and methotrexate intrathecally (IT) on
      days 1, 8, and 22. Patients in complete remission on day 43 proceed to maintenance, those in
      partial remission undergo biopsy then proceed to maintenance, and those with residual disease
      receive radiotherapy on regimen A concurrently with maintenance. Maintenance (day 1 is day 43
      of Induction): Courses of intermediate dose methotrexate/leucovorin calcium and high dose
      cytarabine (ID MTX/CF/HD ARA-C) and modified APO alternate every 3 weeks. Patients receive a
      total of 15 courses (8 of ID MTX/CF/HD ARA-C and 7 of Modified APO). ID MTX/CF/HD ARA-C:
      Patients receive methotrexate IV over 24 hours on day 1, leucovorin calcium IV or orally
      every 6 hours on days 2 and 3, cytarabine IV over 48 hours on days 2 to 4, and methotrexate
      IT on day 1 of courses 1, 3, and 5. Filgrastim (G-CSF) is administered beginning on day 5 and
      continuing until blood counts recover. Modified APO: Patients receive vincristine IV on day
      1, oral mercaptopurine on days 1-5, doxorubicin IV over 15 minutes on day 1, and oral
      prednisone three times a day on days 1-5. Arm II: Induction: Patients receive treatment as in
      arm I except that patients with CNS disease also receive methotrexate IT on days 15, 29, and
      36. Maintenance (day 1 is day 43 of Induction): Modified APO: as in Arm I, with methotrexate
      administered on day 1 of courses 1, 3, and 5 (days 1-5 for patients with CNS disease).
      Courses repeat every 21 days for a total of 15 courses. Patients with CNS disease begin
      radiotherapy on Regimen B on week 2 of maintenance. Regimen A: Patients begin radiotherapy (5
      days a week for 4.5 weeks) to residual tumor on day 1 of maintenance. Regimen B: Patients
      receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of
      maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every
      6 months for 3 years, and annually thereafter.

      PROJECTED ACCRUAL: A total of 242 patients will be accrued for this study over approximately
      5.4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1994</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>Length of study</time_frame>
    <description>To study whether intermediate-dose methotrexate/high-dose Ara-C (ID MTX/HDAra-C), administered during the maintenance phase can improve the event free survival (EFS) of patients with advanced-stage large cell lymphoma (LCL).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients begin radiotherapy (5 days a week for 4.5 weeks) to residual tumor on day 1 of maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every 6 months for 3 years, and annually thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>rmetHuG-CSF</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>NSC #614629</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>CYTOSINE ARABINOSIDE</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>NSC #63878</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>NSC #123127</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>LCV</other_name>
    <other_name>Wellcovorin</other_name>
    <other_name>citrovorum factor</other_name>
    <other_name>folinic acid</other_name>
    <other_name>NSC #3590</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>6-MP</other_name>
    <other_name>Purinethol</other_name>
    <other_name>NSC #755</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>NSC #740</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Liquid Pred</other_name>
    <other_name>NSC #10023</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>VCR</other_name>
    <other_name>Oncovin</other_name>
    <other_name>NSC #67574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET cobalt-60 gamma ray therapy</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET electron therapy</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Previously untreated large cell lymphoma, including the following
        histologic designations: Rappaport classification Diffuse histiocytic Mixed
        lymphocytic-histiocytic Working Formulation classification Diffuse large cell, cleaved
        and/or noncleaved Immunoblastic Diffuse, mixed small and large cell Lukes-Collins
        classification Diffuse large cleaved Diffuse large noncleaved Immunoblastic T or B cell
        True histiocytic Updated Kiel classification Cytocentric large cell
        Centroblastic-centrocytic T-zone Lymphoepithelioid cell (Lennert's) Immunoblastic T or B
        cell Large cell anaplastic Pleomorphic Centroblastic-centrocytic, diffuse Malignant
        histiocytosis Murphy stage III/IV HIV-associated lymphoma eligible Any degree of bone
        marrow involvement eligible CNS disease eligible (such patients not randomized)

        PATIENT CHARACTERISTICS: Age: Under 22 Performance status: Not specified Hepatic: Not
        specified Renal: Not specified Other: Not pregnant or nursing Adequate contraception
        required of fertile patients

        PRIOR CONCURRENT THERAPY: No prior therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph H. Laver, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center-Saint Francis Campus</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-0721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Pediatric Cancer and Blood Disorders Center</name>
      <address>
        <city>Lackland Air Force Base</city>
        <state>Texas</state>
        <zip>78236-5300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center, University of Virginia HSC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico School of Medicine Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Pediatrie</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hutchison RE, Laver JH, Chang M, Muzzafar T, Desai S, Murphy S, Schwenn M, Shuster J, Link MP; Children's Oncology Group. Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Jul;51(1):29-33. doi: 10.1002/pbc.21543.</citation>
    <PMID>18300314</PMID>
  </reference>
  <reference>
    <citation>Hutchison RE, Finch C, Kepner J, Fuller C, Bowman P, Link M, Schwenn M, Laver J, Desai S, Barrett D, Murphy SB. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons. Ann Oncol. 2000;11 Suppl 1:35-8.</citation>
    <PMID>10707776</PMID>
  </reference>
  <results_reference>
    <citation>Nasr MR, Laver JH, Chang M, Hutchison RE. Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: A report from the children's oncology group. Am J Clin Pathol. 2007 May;127(5):770-8.</citation>
    <PMID>17439836</PMID>
  </results_reference>
  <results_reference>
    <citation>Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005 Jan 20;23(3):541-7.</citation>
    <PMID>15659500</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
  <keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

